Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles

Journal of Medicinal Chemistry

Volumn 43, Issue 15, 2000, Pages 2797-2804

  Arris, Christine E ^a   Boyle, F Thomas ^b   Calvert, A Hilary ^a   Curtin, Nicola J ^a   Endicott, Jane A ^c   Garman, Elspeth F ^c   Gibson, Ashleigh E ^a   Golding, Bernard T ^a   Grant, Sharon ^a   Griffin, Roger J ^a   Jewsbury, Philip ^b   Johnson, Louise N ^c   Lawrie, Alison M ^c   Newell, David R ^a,e   Noble, Martin E M ^c   Sausville, Edward A ^d   Schultz, Robert ^d   Yu, Wyatt ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 2,6 DIAMINO 4 CYCLOHEXYLMETHYLOXY 5 NITROSOPYRIMIDINE; 6 O CYCLOHEXYLMETHYLGUANINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; FLAVOPIRIDOL; GUANINE; OLOMOUCINE; PROTEIN SERINE THREONINE KINASE; PURINE; PYRIMIDINE ANTAGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CRYSTAL STRUCTURE; DRUG SENSITIVITY; GENE DELETION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; PROGNOSIS; STRUCTURE ANALYSIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; CDC2-CDC28 KINASES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; MODELS, MOLECULAR; PROTEIN-SERINE-THREONINE KINASES; PURINES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034721195     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990628o     Document Type: Article

References (46)

1. Pines, J. Cyclins and cyclin-dependent kinases: A biochemical view. Biochem. J. 1995, 308, 697-711.
2. Chevalier, S.; Blow, J. J. Cell cycle control of replication initiation in eukaryotes. Curr. Opin. Cell Biol. 1996, 8, 815-821.
3. Nurse, P.; Masui, Y.; Hartwell, L. Understanding the cell cycle. Nature Med. 1998, 4, 1103-1106.
4. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
5. Morgan, D. O. Cyclin-dependent kinases: Engines, Clocks and Microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13, 261-291.
6. Hall, M.; Peters, G. Genetics alterations of cyclins, cyclin-dependent dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68, 67-108.
7. Gray, N.; Detivaud, L.; Doerig, D.; Meijer, L. ATP-site inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-875.
8. Walker, D. H. Small-molecule inhibitors of cyclin-dependent kinases: Molecular tools and potential therapeutics. Curr. Top. Microbiol. Immunol. 1998, 227, 149-165.
9. Garrett, M. D.; Fattaey, A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 1999, 9, 104-111.
10. Senderowicz, A. M.; Headlee, D.; Stinson, S. F.; Lush, R. M.; Kalil, N.; Villalba, L.; Hill, K.; Steinberg, S. M.; Figg, W. D.; Tompkins, A.; Arbuck, S. G.; Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol. 1998, 16, 2986-2999.
11. Drees, M.; Dengler, W. A.; Roth, T.; Labonte, H.; Mayo, J.; Malspeis, L.; Grever, M.; Sausville, E. A.; Fiebig, H. H. Flavopiridol (L86-8275): Selective antitumour activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. 1997, 3, 2273-279.
12. Arguello, F.; Alexander, M.; Sterry, J. A.; Tudor, G.; Smith, E. M.; Kalavar, N. T.; Greene, J. F.; Koss, W.; Morgan, C. D.; Stinson, S. F.; Siford, T. J.; Alvord, W. G.; Klabansky, R. L.; Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumour activity in vivo against human leukaemia and lymphoma xenografts. Blood 1998, 91, 2482-2490.
13. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996, 56, 2973-2978.
14. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. JNCI, J. Natl. Cancer Inst. 1992, 84, 1736-1740.
15. Schrump, D. S.; Matthews, W.; Che, G. A.; Mixon, A.; Altorki, N. K. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin. Cancer. Res. 1998, 4, 2885-2890.
16. Parker, B. W.; Kaur, G.; Nieves-Neira, W.; Taimi, M.; Kohlhagen, G.; Taimi, M.; Kohlhagen, G.; Shimizu, T.; Losiewicz, M. D.; Pommier, Y.; Sausville, E. A.; Senderowicz, A. M. Early induction of apoptosis in haematopoietic cell lines after exposure to flavopiridol. Blood 1998, 91, 458-465.
17. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.-Y.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
18. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J.-L.; Moulinoux, J.-P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
19. Brooks, E. E.; Gray, N. S.; Joly, A.; Kerwar, S. S.; Lum, R.; Mackman, R. L.; Norma, T. C.; Rosete, J.; Rowe, M.; Schow, S. R.; Schultz, P. G.; Wang, X.; Wick, M. M.; Schiffman, D. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 1997, 272, 29207-29211.
20. Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Schiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Synthesis and activity of 2,6,9-trisubstituted purines. Bioorg. Med. Chem. Lett. 1997, 7, 2697-2702.
21. Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
22. LeGraverend, M.; Ludwig, O.; Bisagni, E.; LeClerc, S.; Meijer, L. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. 1998, 8, 793-798.
23. Imbach, P.; Capraro, H.-G.; Furet, P.; Mett, H.; Meyer, T.; Zimmermann, J. 2,6,9-Trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 91-96.
24. Chang, Y.-T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, M.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
25. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S.-H. Multiple modes of ligand recognition: Crystal structure of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 1995, 22, 378-391.
26. de Azevedo, W. F., Jr.; LeClerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S.-H. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
27. 6-alkylguanine-DNA alkyltransferase with substrate analogues. Anticancer Drug Design 1994, 9, 401-408.
28. Lembicz, N. K.; Grant, S.; Clegg, W.; Griffin, R. J.; Heath, S. L.; Golding, B. T. Facilitation of displacements at the 6-position of purines by the use of 1,4-diazabicyclo[2,2,2]octane as leaving group. J. Chem. Soc., Perkin Trans, 1 1997, 185-186.
29. Pfleiderer, W.; Lohrmann, R. Synthesis of 2-amino-4-alkoxypteridine. Chem. Ber. 1961, 94, 12-18.
30. Brown, N. R.; Noble, M. E. M.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. Effects of phosphorylation of threonine 160 on CDK2 structure and activity. J. Biol. Chem. 1999, 274, 8746-8756.
31. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine: Details of the molecular interaction determined by the X-ray crystallographic analysis of a CDK2-staurosporine complex. Nature Struct. Biol. 1997, 4, 796-802.
32. Otwinowski, Z. Oscillation data reduction program. In DL/SC1/R34; Sawyer, L., Isaacs, N., Bailey, S., Eds.; SERC Laboratory: Daresbury, Warrington, U.K., 1993; pp 56-62.
33. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved method for building models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47, 110-119.
34. Sybyl Molecular Modelling Software; Tripos Associates Inc.: St. Louis, MO, 1992.
35. Murshudov, G. N.; Vagen, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.
36. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 1994, D50, 760-763.
37. Lamzin, V. S.; Wilson, K. S. Automated refinement of protein models. Acta Crystallogr. 1993, D49, 129-147.
38. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. JNCI, J. Natl. Cancer Inst. 1991, 83, 757-766.
39. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. JNCI, J. Natl. Cancer Inst. 1989, 81, 1088-1092.
40. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S.-H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
41. de Azevedo, W., Jr.; Mueller-Dieckmann, H.-J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
42. Hoessel, R.; Leclerc, S.; Endicott, J. A.; Noble, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1999, 1, 60-67.
43. Russo, A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struct. Biol. 1996, 3, 696-700.
44. Ongkeko, W.; Ferguson, D. J. P.; Harris, A. L.; Norbury, C. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. 1995, 108, 2897-2904.
45. Connolly, M. Molecular surface triangulation. J. Appl. Crystallogr. 1985, 18, 499-505.
46. Goodford, P. Multivariate characterization of molecules for QSAR. J. Chemom. 1996, 10, 107-117.